CSIMarket
 


Prothena Corporation Public Limited Company  (PRTA)
Other Ticker:  
 

Prothena Public Limited's Leverage Ratio

PRTA's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 4.11%, Leverage Ratio fell to 0.24, below the Prothena Public Limited's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 33 other companies have achieved lower Leverage Ratio than Prothena Public Limited in the IV Quarter 2023. While Leverage Ratio total ranking has deteriorated compared to the third quarter 2023 from 106 to 171 .

Explain Leverage Ratio?
Who are PRTA Customers?
What are PRTA´s Total Liabilities?


PRTA Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change -9.75 % 52.53 % 42.81 % 38.4 % 33.47 %
Y / Y Total Liabilities Change -0.72 % -13.42 % -2.33 % -5.86 % -5.11 %
Leverage Ratio MRQ 0.24 0.21 0.24 0.22 0.22
PRTA's Total Ranking # 171 # 106 # 396 # 513 # 169
Seq. Equity Change -9.05 % 6.11 % -4.24 % -2.35 % 53.72 %
Seq. Total Liabilities Change 4.11 % -6.68 % 3.57 % -1.34 % -9.21 %



Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 34
Healthcare Sector # 54
Overall Market # 171


Leverage Ratio Statistics
High Average Low
0.81 0.27 0.02
(Dec 31 2020)   (Jun 30 2015)




Financial Statements
Prothena Public Limited's Equity $ 561 Millions Visit PRTA's Balance sheet
Prothena Public Limited's Total Liabilities $ 135 Millions Visit PRTA's Balance sheet
Source of PRTA's Sales Visit PRTA's Sales by Geography


Cumulative Prothena Public Limited's Leverage Ratio

PRTA's Leverage Ratio for the trailling 12 Months

PRTA Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth -9.75 % 52.53 % 42.81 % 38.4 % 33.47 %
Y / Y Total Liabilities TTM Growth -0.72 % -13.42 % -2.33 % -5.86 % -5.11 %
Leverage Ratio TTM 0.23 0.22 0.25 0.28 0.3
Total Ranking TTM # 1 # 2 # 1 # 3 # 298
Seq. Equity TTM Growth -9.05 % 6.11 % -4.24 % -2.35 % 53.72 %
Seq. Total Liabilities TTM Growth 4.11 % -6.68 % 3.57 % -1.34 % -9.21 %


On the trailing twelve months basis Due to the net new borrowings of 4.11% during the trailing twelve months finishing in the IV Quarter 2023, cumulativeLeverage Ratio improved to 0.23, below the Prothena Public Limited's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry PRTA recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 1, from total ranking in previous 12 month period at 2.

Explain Leverage Ratio?
Who are PRTA Customers?
What are PRTA´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 1


trailing twelve months Leverage Ratio Statistics
High Average Low
0.68 0.32 0.04
(Mar 31 2021)   (June 30. 2015)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Equity
Acurx Pharmaceuticals inc   0.65 $ 3.042  Millions$ 4.667  Millions
Beigene ltd   0.64 $ 2,267.948  Millions$ 3,537.327  Millions
Ovid Therapeutics Inc   0.63 $ 54.984  Millions$ 87.797  Millions
Ampio Pharmaceuticals inc   0.63 $ 2.102  Millions$ 3.360  Millions
23andme Holding Co  0.61 $ 231.023  Millions$ 377.188  Millions
Elite Pharmaceuticals Inc   0.61 $ 28.283  Millions$ 46.414  Millions
Nature s Sunshine Products inc   0.60 $ 95.715  Millions$ 159.540  Millions
Bicycle Therapeutics Plc  0.58 $ 215.030  Millions$ 370.932  Millions
Madrigal Pharmaceuticals Inc   0.58 $ 233.501  Millions$ 405.333  Millions
Werewolf Therapeutics Inc   0.57 $ 63.459  Millions$ 111.374  Millions
Hookipa Pharma inc   0.53 $ 48.005  Millions$ 89.857  Millions
Harmony Biosciences Holdings inc   0.52 $ 244.962  Millions$ 466.992  Millions
Dermata Therapeutics Inc   0.51 $ 3.247  Millions$ 6.355  Millions
Capricor Therapeutics inc   0.49 $ 11.113  Millions$ 22.601  Millions
Cymabay Therapeutics Inc   0.49 $ 142.430  Millions$ 292.256  Millions
Earth Science Tech Inc   0.48 $ 1.041  Millions$ 2.159  Millions
Lumos Pharma Inc   0.48 $ 13.051  Millions$ 27.305  Millions
Legend Biotech Corporation  0.48 $ 597.238  Millions$ 1,251.371  Millions
Theriva Biologics inc   0.47 $ 17.528  Millions$ 36.963  Millions
Moleculin Biotech Inc   0.47 $ 12.144  Millions$ 26.073  Millions
Schrodinger Inc   0.46 $ 254.397  Millions$ 548.558  Millions
Talphera Inc   0.45 $ 6.290  Millions$ 14.105  Millions
Xencor Inc  0.42 $ 283.896  Millions$ 669.133  Millions
Arrowhead Pharmaceuticals Inc   0.42 $ 73.609  Millions$ 173.714  Millions
Salarius Pharmaceuticals inc   0.41 $ 2.192  Millions$ 5.287  Millions
Avenue Therapeutics Inc   0.41 $ 0.268  Millions$ 0.654  Millions
Oncolytics Biotech Inc   0.41 $ 8.623  Millions$ 21.113  Millions
Anaptysbio Inc   0.40 $ 35.665  Millions$ 88.103  Millions
Arcus Biosciences Inc   0.40 $ 184.000  Millions$ 462.000  Millions
Integrated Biopharma Inc  0.39 $ 7.155  Millions$ 18.566  Millions

Date modified: 2024-02-23T12:42:43+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com